Current cancer immunotherapy [eg, immune checkpoint blockade (ICB)] only benefits small
subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In …

Immunotherapy, an attractive option for cancer treatment, necessitates the direct stimulation
of immune cells in vivo and the simultaneous effective inhibition of immunosuppressive …

Despite the great promise achieved by immune checkpoint blockade (ICB) therapy in
harnessing the immune system to combat different tumors, limitations such as low objective …

Immunotherapy holds great promise for the treatment of malignant cancer. However, the lack
of sufficient tumor neoantigens and incomplete dendritic cell (DC) maturation compromise …

Vaccines are one of utmost important weapons in modern medicine to fight a wide range of
diseases. To achieve optimal vaccination effects, repeated injections of vaccines are often …

Although neoantigen-based cancer vaccines show great potential in cancer immunotherapy
due to their ability to induce effective and long-lasting anti-tumor immunity, their …

Nanovaccine‐based immunotherapy (NBI) has received greater attention recently for its
potential to prime tumor‐specific immunity and establish a long‐term immune memory that …

Cancer nanovaccines have the ability to train the immune system to specifically recognize
and eliminate tumor cells. However, the vaccine's efficacy is hampered by limited access to …

Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy,
a monotherapy approach is not sufficient. Here, we report an immune checkpoint inhibitor …

Tumor vaccine is a promising cancer treatment modality, however, the convenient antigens
loading in vivo and efficient delivery of vaccines to lymph nodes (LNs) still remain a …